Patient capital rejected the Firmus IPO because the valuation relied on aspirations rather than earnings. Despite strong backing from major investors and extensive marketing support, long-term investors could not justify paying for a business with no earnings, no clear profitability forecast and significant future borrowing requirements.
The key risk was the gap between project-level targets and company-level economics. Firmus promoted ambitious revenue and EBIT targets, but investors were left without a consolidated forecast that accounted for corporate costs, debt financing, interest expenses and GPU amortisation.
The failed float highlights the importance of independent analysis over sales-driven narratives. Unconflicted investors focused on valuation, financing and risk, while the IPO structure rewarded parties paid to place the stock rather than those responsible for long-term investment outcomes.
A project's margin isn't the company's. Ask what sits between the headline EBITDA and the net profit you'd actually own. In Firmus’s case, that meant debt finance and GPU amortisation costs. If management won't add up and present the numbers to you, treat them as marketing.